Uniting for the uncommon: Successes and lessons in pharma-patient advocacy partnerships
What the audience will learn:
This will be a transparent discussion on the types of collaborations and agreements that have worked (or not worked) between rare disease patient advocacy groups and drug development companies.
Learn what you’re doing right (or wrong!) when trying to build bridges with advocacy organizations.
Learn key questions to ask about advocacy organizations and drug companies before starting a partnership.